Abstract:Abstract Three-dimensional (3D) disease models have garnered widespread interest for use in later stages of the drug discovery process, such as preclinical efficacy and toxicology studies, due to their pathophysiologically relevant properties. However, there is a need and opportunity for 3D cancer models to be used earlier in the drug screening process. To meet this need, the 3D models must strike a balance between throughput, which includes scalability and uniformity, and physiological relevance, such as the ability to modulate key attribute of the tumor microenvironment. Here we report the creation of 3D colorectal cancer (CRC) tissue models, referred to as VivoSpheres, and demonstrated their relevance to cancer drug screening. The VivoSphere production platform couples tissue engineering toolkits with microfluidics, enabling the scalable production of engineered cancer microspheres. The model supports the long-term maintenance of the cancer cell phenotype. In a preliminary study, we were able to generate more physiologically relevant drug responses. We formed CRC VivoSpheres by encapsulating HT-29 CRC cells within poly(ethylene glycol)-fibrinogen hydrogel microspheres using our previously developed microfluidic platform. CRC VivoSpheres were rapidly produced with high cell densities (20 × 106 cells/ml) and high uniformity on day 0 with a coefficient of variation (COV) < 7%. This high uniformity was maintained for 15 days (COV ≤ 10%), which is critical for long-term dose studies. The cells maintained high viability and showed high proliferative capability with a significant increase in colony size and expression of Ki67 up to day 29. The encapsulated cells maintained the CRC phenotype over time with the expression of CD44 (cancer stem cell marker) and CK20 (CRC marker). After establishing shipping conditions that maintained cell viability for remote use, the HT-29 VivoSpheres were shipped to the oncology team at Southern Research for drug testing. The CRC VivoSpheres were treated with DMSO, GANT61, and SRI-38832, the latter two of which are GLI1 inhibitors. Phase contrast images and western blot were used to assess the response of CRC VivoSpheres to the treatments. Oncogenic GLI1 transcription activity and NBS1 overexpression have been found to contribute to chemotherapeutic resistance, negating the anti-tumor effects of 5-fluorouracil. While 2D cultured HT-29s responded to treatment with GANT61, HT-29 VivoSpheres continued to express NBS1 following GANT1 treatment, but downregulated NBS1 in response to the GLI1 inhibitor SRI-38832, which is the same response Southern Research has seen in in vivo tumor models. In conclusion, we have developed tissue-engineered 3D CRC models that hold promise for use in drug screening. These models have demonstrated an initial capability to reproduce the CRC phenotype and mimic in vivo drug response. Citation Format: Yuan Tian, Mohammadjafar Hashemi, Benjamin Anbiah, Ruowen Zhang, Iman Hassani, Rebecca Boohaker, Elizabeth Lipke. Tissue engineered colorectal cancer microspheres for drug screening [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6773.

Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry

Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry

3D Cell-Based Biosensor for Cell Viability and Drug Assessment by 3D Electric Cell/matrigel-Substrate Impedance Sensing.

3D Microgroove Electrical Impedance Sensing to Examine 3D Cell Cultures for Antineoplastic Drug Assessment

A Novel Micro-Groove Impedance Sensor for 3D Cell Viability Monitoring and High-Throughput Drug Screening

Enabling high throughput drug discovery in 3D cell cultures through a novel bioprinting workflow

3D Tumer Cell System for in Vitro Screening of Chemotherapeutic Drugs

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

Fluorescence‐Guided Spatial Drug Screening in 3D Colorectal Cancer Spheroids

3D Bioprinting of in Vitro Porous Hepatoma Models: Establishment, Evaluation, and Anticancer Drug Testing

Assessing drug uptake and response differences in 2D and 3D cellular environments using stimulated Raman scattering microscopy

Label-free acoustic and optical microscopy of live tumor spheroids in hydrogel for high-throughput 3D In-vitro drug screening

The Design and Fabrication of a Porous Polymer-Based Three-Dimensional Cell Culture Device for Drug Screening

High-Throughput 3D Tumor Spheroid Screening Method for Cancer Drug Discovery Using Celigo Image Cytometry

Assessment and process optimization of high throughput biofabrication of immunocompetent breast cancer model for drug screening applications

Untargeted Metabolite Mapping in 3D Cell Culture Models Using High Spectral Resolution FT-ICR Mass Spectrometry Imaging

Bi-layer Blood Vessel Mimicking Microfluidic Platform for Antitumor Drug Screening Based on Co-Culturing 3D Tumor Spheroids and Endothelial Layers.

Evaluation of AMG510 Therapy on KRAS-Mutant Non–Small Cell Lung Cancer and Colorectal Cancer Cell Using a 3D Invasive Tumor Spheroid System under Normoxia and Hypoxia

Abstract 6773: Tissue engineered colorectal cancer microspheres for drug screening

Empowering High Throughput Screening of 3D Models: Automated Dispensing of Cervical and Endometrial Cancer Cells

3D bioprinting platform development for high-throughput cancer organoid models construction and drug evaluation